Sirolimus Tablet 1 & 2g

Sirolimus  Tablet 1 & 2g is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. Therapeutic drug monitoring is recommended for all patients receiving Rapamune.In patients at low- to moderate-immunologic risk, it is recommended that Rapamune be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation.In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level > 80%]), it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation .

There are many generic manufacturers in India who manufacture Sirolimus  Tablet 1 & 2g including Cadila Healthcare Ltd etc.

3s corporation is Supplier,Exporter ,Wholesaler  for Sirolimus  Tablet 1 & 2g in India.

Sirolimus  Tablet 1 & 2g  should be stored at 20° to  25°C . Use cartons to protect blister cards and strips from light.  Dispense in a tight, light-resistant container.

• Increased susceptibility to infection, lymphoma, and malignancy .
• Excess mortality, graft loss, and hepatic artery thrombosis in liver transplant patients.
• Bronchial anastomotic dehiscence in lung transplant patients.
• Hypersensitivity reactions.
• Exfoliative dermatitis .
• Angioedema
• Fluid Accumulation and Wound Healing
• Hypertriglyceridemia, hypercholesterolemia
• Decline in renal function in long-term combination of cyclosporine with Rapamune
• Proteinuria
• Interstitial lung disease
• Increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) .